To include your compound in the COVID-19 Resource Center, submit it here.

Syncona leads CHF35 million A round for Anaveon

Anaveon AG (Zurich, Switzerland) closed the first undisclosed tranche of a CHF35 million ($35 million) series A round Tuesday to help bring its biologic IL-2 receptor agonists into the clinic. Syncona Ltd.

Read the full 328 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers